Mar 14 |
3 Pharma Stocks to Sell in March Before They Crash & Burn
|
Mar 13 |
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
|
Mar 13 |
Evaluating Acadia's Market Position Following Pimavanserin's Clinical Setback
|
Mar 12 |
Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
|
Mar 12 |
Mizuho cuts Acadia to neutral, cites lack of upcoming catalysts
|
Mar 12 |
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
|
Mar 12 |
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
|
Mar 12 |
Biggest stock movers today: LUV, ORCL, ACAD, and more
|
Mar 12 |
Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: Details
|
Mar 11 |
UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study
|